首页> 美国卫生研究院文献>Journal of Radiation Research >Comparison of adverse effects of proton and X-ray chemoradiotherapy for esophageal cancer using an adaptive dose–volume histogram analysis
【2h】

Comparison of adverse effects of proton and X-ray chemoradiotherapy for esophageal cancer using an adaptive dose–volume histogram analysis

机译:利用自适应剂量-体积直方图分析比较质子和X射线放化疗对食管癌的不良反应

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Cardiopulmonary late toxicity is of concern in concurrent chemoradiotherapy (CCRT) for esophageal cancer. The aim of this study was to examine the benefit of proton beam therapy (PBT) using clinical data and adaptive dose–volume histogram (DVH) analysis. The subjects were 44 patients with esophageal cancer who underwent definitive CCRT using X-rays (n = 19) or protons (n = 25). Experimental recalculation using protons was performed for the patient actually treated with X-rays, and vice versa. Target coverage and dose constraints of normal tissues were conserved. Lung V5–V20, mean lung dose (MLD), and heart V30–V50 were compared for risk organ doses between experimental plans and actual treatment plans. Potential toxicity was estimated using protons in patients actually treated with X-rays, and vice versa. Pulmonary events of Grade ≥2 occurred in 8/44 cases (18%), and cardiac events were seen in 11 cases (25%). Risk organ doses in patients with events of Grade ≥2 were significantly higher than for those with events of Grade ≤1. Risk organ doses were lower in proton plans compared with X-ray plans. All patients suffering toxicity who were treated with X-rays (n = 13) had reduced predicted doses in lung and heart using protons, while doses in all patients treated with protons (n = 24) with toxicity of Grade ≤1 had worsened predicted toxicity with X-rays. Analysis of normal tissue complication probability showed a potential reduction in toxicity by using proton beams. Irradiation dose, volume and adverse effects on the heart and lung can be reduced using protons. Thus, PBT is a promising treatment modality for the management of esophageal cancer.
机译:食管癌的同步放化疗(CCRT)中,心肺晚期毒性值得关注。这项研究的目的是使用临床数据和自适应剂量-体积直方图(DVH)分析来检查质子束治疗(PBT)的益处。受试者为44例食管癌患者,他们使用X射线(n = 19)或质子(n = 25)进行了明确的CCRT。对于实际用X射线治疗的患者,使用质子进行了实验性的重新计算,反之亦然。保留了正常组织的靶标覆盖范围和剂量限制。比较实验计划和实际治疗计划之间的风险器官剂量,比较肺V5-V20,平均肺部剂量(MLD)和心脏V30-V50。使用质子估计实际接受X射线治疗的患者的潜在毒性,反之亦然。 ≥2级的肺事件发生在8/44例中(占18%),而心脏事件发生在11例中(占25%)。 ≥2级事件的患者的危险器官剂量显着高于≤1级事件的患者的危险器官剂量。质子计划中的危险器官剂量低于X射线计划。所有接受过X射线治疗的毒性患者(n = 13)均使用质子降低了肺部和心脏的预测剂量,而所有接受过≤1级毒性的质子治疗(n = 24)的患者的预期毒性均降低了用X射线。正常组织并发症的可能性分析表明,使用质子束可潜在降低毒性。质子可以减少辐照剂量,体积以及对心脏和肺部的不利影响。因此,PBT是食管癌治疗的一种有前途的治疗方式。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号